USA - NASDAQ:NSPR - US45779A8466 - Common Stock
The current stock price of NSPR is 2.11 USD. In the past month the price decreased by -13.35%. In the past year, price decreased by -7.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.62 | 37.15B | ||
| COO | COOPER COS INC/THE | 17.13 | 13.69B | ||
| SOLV | SOLVENTUM CORP | 11.13 | 11.74B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.19 | 9.95B | ||
| BLCO | BAUSCH + LOMB CORP | 36.58 | 5.57B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.42 | 5.16B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.96 | 3.89B | ||
| ICUI | ICU MEDICAL INC | 16.94 | 3.15B | ||
| XRAY | DENTSPLY SIRONA INC | 7.38 | 2.52B | ||
| HAE | HAEMONETICS CORP/MASS | 10.91 | 2.44B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.32 | 1.81B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.75B |
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
INSPIREMD INC
6303 Waterford District Drive, Suite 215
Miami FLORIDA 6744832 US
CEO: Marvin Slosman
Employees: 86
Phone: 18887766804
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
The current stock price of NSPR is 2.11 USD. The price decreased by -0.94% in the last trading session.
NSPR does not pay a dividend.
NSPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NSPR stock is listed on the Nasdaq exchange.
8 analysts have analysed NSPR and the average price target is 4.59 USD. This implies a price increase of 117.54% is expected in the next year compared to the current price of 2.11.
The outstanding short interest for INSPIREMD INC (NSPR) is 0.38% of its float.
ChartMill assigns a fundamental rating of 3 / 10 to NSPR. NSPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months NSPR reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.11% | ||
| ROE | -204.42% | ||
| Debt/Equity | 0 |
8 analysts have analysed NSPR and the average price target is 4.59 USD. This implies a price increase of 117.54% is expected in the next year compared to the current price of 2.11.
For the next year, analysts expect an EPS growth of -12.46% and a revenue growth 7.09% for NSPR